Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile–Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation

Pharmacotherapy

Volumn 37, Issue 12, 2017, Pages 1489-1497

  Reveles, Kelly R ^a,b   Backo, Jennifer L ^c   Corvino, Frank A ^d   Zivkovic, Marko ^d   Broderick, Kelly C ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Genesis Research Limited   (United States)

Author keywords

Clostridium difficile; costs; fidaxomicin; vancomycin

Indexed keywords

FIDAXOMICIN; VANCOMYCIN; AMINOGLYCOSIDE;

AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; COST CONTROL; DRUG COST; ECONOMIC EVALUATION; HOSPITALIZATION COST; HUMAN; RECURRENT DISEASE; SENSITIVITY ANALYSIS; CLOSTRIDIUM INFECTION; COMPARATIVE STUDY; COMPLICATION; DIARRHEA; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; HOSPITALIZATION; STATISTICS AND NUMERICAL DATA;

AMINOGLYCOSIDES; CLOSTRIDIUM INFECTIONS; COST SAVINGS; DIARRHEA; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; VANCOMYCIN;

EID: 85035207089     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.2049     Document Type: Article

References (35)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;13:1198–208.
2. Centers for Disease Control and Prevention. Antibiotic resistant threats in the United States, 2013. Available from http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed March 6, 2015.
3. Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control 2014;10:1028–32.
4. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP Statistical Brief 124. January 2012. Rockville, MD: Agency for Healthcare Research and Quality. Available from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf. Accessed December 27, 2011.
5. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;4:281–9.
6. Wenisch JM, Schmid D, Tucek G, et al. A prospective cohort study on hospital mortality due to Clostridium difficile infection. Infection 2012;5:479–84.
7. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989;2:340–3.
8. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014;3:345–54.
9. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;7:1769–75.
10. Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;11:2892–900.
11. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;5:422–31.
12. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013;19:2493–9.
13. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011;5:440–7.
14. Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol 2013;1:1–11.
15. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;5:431–55.
16. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012;55:S93–103.
17. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012;55:S154–61.
18. Dubberke ER, Schaefer E, Reske KA, Zilberberg M, Hollenbeak CS, Olsen MA. Attributable inpatient costs of recurrent Clostridium difficile infections. Infect Control Hosp Epidemiol 2014;11:1400–7.
19. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008;9:823–8.
20. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;11:1219–27.
21. Aitken SL, Joseph TB, Shah DN, et al. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One 2014;7:e102848.
22. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;2:297–304.
23. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;11:1507–14.
24. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis Clin Infect Dis 2013;4:555–61.
25. Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol 2014;2:87–94.
26. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014;11:2901–12.
27. Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother 2015;11:7007–10.
28. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;3:197–205.
29. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;6:758–64.
30. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;1:43–50.
31. Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis 2016;1:447.
32. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;6:403–10.
33. DuPont HL. The search for effective treatment of Clostridium difficile infection. N Engl J Med 2011;5:473–5.
34. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;3:324–33.
35. Centers for Medicare and Medicaid Services. Readmissions Reduction Program. Available from http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html. Accessed March 6, 2015.